<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/314A3F92-9F78-4782-891F-990F9E739DC4"><gtr:id>314A3F92-9F78-4782-891F-990F9E739DC4</gtr:id><gtr:name>Medical University of Vienna</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/314A3F92-9F78-4782-891F-990F9E739DC4"><gtr:id>314A3F92-9F78-4782-891F-990F9E739DC4</gtr:id><gtr:name>Medical University of Vienna</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4BD46A99-6CCE-45C4-A615-3C8DBE0AC41D"><gtr:id>4BD46A99-6CCE-45C4-A615-3C8DBE0AC41D</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Rees</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1DDC8BB0-1F31-4F4A-9CC7-466A27A3EA67"><gtr:id>1DDC8BB0-1F31-4F4A-9CC7-466A27A3EA67</gtr:id><gtr:firstName>Heather</gtr:firstName><gtr:otherNames>Marion</gtr:otherNames><gtr:surname>Wilson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/849D6621-B847-4B64-A241-5DF577911EC3"><gtr:id>849D6621-B847-4B64-A241-5DF577911EC3</gtr:id><gtr:firstName>Renate</gtr:firstName><gtr:surname>Kain</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500711"><gtr:id>324B3A5A-36A4-4D5E-9C02-50B63DC5DA41</gtr:id><gtr:title>Deviating macrophage activation in glomerulonephritis by SOCS proteins</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0500711</gtr:grantReference><gtr:abstractText>Renal failure is an enormous financial, physical and emotional burden worldwide and a significant cause of morbidity and mortality. At present transplantation or dialysis is the only treatment for this disabilitating disease and the only way to prevent this is devise much more effective ways to treat kidney diseases that cause progressive injury and eventually destroy the kidney. We have developed a programme of research with this purpose that focuses on the role of infiltrating macrophages, important white blood cells that are a common feature of all types of severe and progressive kidney disease. Much of the work on macrophages is based on their ability to cause tissue injury however it is now apparent that macrophages can also facilitate resolution of injury and promote tissue repair. Our research aims to inhibit the destructive properties and harness the reparative potential of macrophages so to create therapeutic cells for treatment of inflammatory diseases. We have developed proof of this principal by inhibiting specific macrophage intracellular signalling pathways to create an anti-inflammatory therapeutic macrophage that down regulates renal inflammation in experimental models. We now want to expand our research to use more natural methods of developing macrophages to become therapeutic cells and for this purpose we will investigate the role of suppressors of cytokine signalling (SOCS) family of which two (SOCS1 and SOCS3) have an important role in macrophages. We hypothesise that the expression of these proteins will have a powerful effect on the properties macrophages develop in inflamed tissue and changing their expression in macrophages could have a influential effect on inhibiting progression of renal inflammation. If our hypothesis is correct this could form the basis of much more effective treatments for kidney disease as well as other types of inflammatory disorders.</gtr:abstractText><gtr:technicalSummary>The purpose of our work is to develop more effective treatments for glomerulonephritis, using macrophages as therapeutic targets. Our approach exploits the plasticity of macrophage function and aims to deviate their responses so that they develop reparative rather than destructive properties when activated after infiltrating an acutely inflamed glomerulus. We have already established that this can be done by genetically manipulating macrophages so the NFkB signalling is inhibited an IkB superrepressor (Wilson et al., Am.J.Path. 2005; in press). We hypothesise that macrophages will have natural mechanisms to achieve such deviation, and that the suppressors of cytokine signalling (SOCS) proteins, SOCS1 and SOCS3, will be central to this process. Consequently, we propose to use novel strategies for examining macrophage activation in vivo to: (i) determine the importance of SOCS1 and SOCS3 in the development and maintenance of specific macrophage activation states; (ii) characterise SOCS1 and SOCS3 expression in infiltrating glomerular macrophages during the evolution of acute experimental nephritis; and to determine their ability to block specific cytokine signalling pathways and direct macrophage activation at the different phases of the disease; and (iii) ascertain whether macrophages over-expressing SOCS1 and/or SOCS3 are biased toward an anti-inflammatory type that is capable of attenuating renal injury in vivo. These results should provide novel information about the role (if any) of SOCS proteins in directing the function of inflammatory macrophages in glomerulonephritis, and should have implications for other macrophage dependent diseases.</gtr:technicalSummary><gtr:fund><gtr:end>2010-02-08</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-09</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>257358</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Immunology and Infection Research</gtr:department><gtr:description>Judith Allen Institute of Immunology and Infection Research, University of Edinburgh</gtr:description><gtr:id>9ADA9553-57C1-49EF-B501-605DA830AD8B</gtr:id><gtr:impact>Manuscript now in its final draft, presentations at meetings, published abstracts</gtr:impact><gtr:outcomeId>17559F3E124-1</gtr:outcomeId><gtr:partnerContribution>University of Edinburgh have provided BALB/c mouse peritoneal macrophages activated in a microenvironment that drives M2 polarisation. These are induced by implanting mice intraperitoneally with the filiarial nematode Brugia malayi. As a comparison, peritoneal macrophages were also collected from the infected peritoneum of mice deficient in IL-4 receptor that do not support IL-4 mediated activation. The laboratory at the University of Edinburgh has also characterised the phenotype (M1 or M2) of these macrophages.</gtr:partnerContribution><gtr:piContribution>We initiated the collaboration because of Professor Allen's experimental system of inducing a Th2 type peritoneal inflammation would enable us to test the role of SOCS1 in macrophage polarisation. The laboratories at Aberdeen determined the SOCS1 and 3 expressions by immunohistochemical analyses, collated data and performed statistical analyses. Financial contribution - in kind</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical University of Vienna</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:description>D. Kerjaschki: Medical University of Vienna. Analysis of SOCS protein expression in human glomerulonephritis</gtr:description><gtr:id>138BAD9F-2CB4-4FD2-AF5E-389751A11DC2</gtr:id><gtr:impact>Currently, methods for analysis have been optimised and SOCS expression by macrophages have been assessed in normal human kidneys (little of no expression) and in in the following pathological situations: T0 renal allografts; pauci-immune focal necrotizing glomerulonephritis and membranous nephropathy all of which show increased SOCS protein expression. Correlation with clinicals data should result in publication.</gtr:impact><gtr:outcomeId>691839046AB-1</gtr:outcomeId><gtr:partnerContribution>MUW have provided clinical renal biopsies for analysis of SOCS protein expression.</gtr:partnerContribution><gtr:piContribution>All technical and analytical work is done by my team: the renal biopsies and clinical data are supplied by MUW</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>119513</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Kidney Research Uk project grant</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Kidney Research UK</gtr:fundingOrg><gtr:fundingRef>RP1/2012</gtr:fundingRef><gtr:id>37FB446C-634B-43E8-B3D0-A91AEFC31C35</gtr:id><gtr:outcomeId>KkKkEZmyTmd</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>364467</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Marie Curie Excellence Chair</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>Marie Sklodowska-Curie Actions</gtr:fundingOrg><gtr:id>EF693A8C-0091-4B97-9374-E32EDEC436AC</gtr:id><gtr:outcomeId>iQqUvVnuMso0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>8935</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NHS Grampian Endowment Fund</gtr:department><gtr:description>Grampian NHS Endowment Grant for Research Project</gtr:description><gtr:end>2010-11-02</gtr:end><gtr:fundingOrg>NHS Grampian</gtr:fundingOrg><gtr:id>4D733189-40D3-4E37-B95A-D529A585FA95</gtr:id><gtr:outcomeId>A9DBF7C0DF30</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>The Cunningham Trust</gtr:department><gtr:description>Cunningham Trust, Project Grant</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>University of St Andrews</gtr:fundingOrg><gtr:id>A0E8C8B5-6516-4161-8738-545F4F86BF29</gtr:id><gtr:outcomeId>FDE5D6CC85B0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>167000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wyeth Pharmaceuticals</gtr:department><gtr:description>TMRC Project Grant</gtr:description><gtr:end>2009-04-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>610C2B67-51AD-4F33-84EC-F23DA72EBE1A</gtr:id><gtr:outcomeId>57BAD7936750</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2006-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Developed and optimised siRNA knock down techniques in rat bone marrow derived macrophages and used the technique to knock down SOCS1 and SOCS3 family proteins. Methods now published.</gtr:description><gtr:id>8E32D61A-871A-4AC0-8641-440AE73EE567</gtr:id><gtr:impact>This enabled us for the first time to examine the role of SOCS proteins in the differential control of macrophage activation in vitro and in vivo using adoptively transferred macrophages.</gtr:impact><gtr:outcomeId>DBAFD7BC784</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>siRNA knock down of SOCS proteins in rat macrophages</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Developed kidney tissue microarrays for analysis of SOCS protein expression in rats with glomerulonephritis. These were originally used to analyse SOCS protein expression as part of the MRC funded project and are now being used to analyse signalling in renal infiltrating macrophages.</gtr:description><gtr:id>94039BEE-E1A7-434F-985A-4BECEE68DB47</gtr:id><gtr:impact>The same approach was translated for studies of macrophages infiltrating human breast cancers.</gtr:impact><gtr:outcomeId>A13ED23EF68</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Renal tissue microarrays for analysis</gtr:title><gtr:type>Data analysis technique</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>conditions for transfection of human cells without activation</gtr:description><gtr:id>7CC6B35D-7A36-4642-BCE3-1CD466624A6D</gtr:id><gtr:impact>we have translated our results in rodent cells to the human system</gtr:impact><gtr:outcomeId>V66eHcGUHEv</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>siRNA transfection and knockdown in human macrophages</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2126E8A2-01E5-425A-9DC3-3EDAE8587D30</gtr:id><gtr:title>Characterisation of tumour-infiltrating macrophages: impact on response and survival in patients receiving primary chemotherapy for breast cancer.</gtr:title><gtr:parentPublicationTitle>Breast cancer research and treatment</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a9c83ab282c566d4c0d984104e73e774"><gtr:id>a9c83ab282c566d4c0d984104e73e774</gtr:id><gtr:otherNames>Heys SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0167-6806</gtr:issn><gtr:outcomeId>pm_15298_28_22886449</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31026840-524C-4283-B9A4-D5668712C01E</gtr:id><gtr:title>Suppressor of cytokine signaling (SOCS)1 is a key determinant of differential macrophage activation and function.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0189805500255a2b81f79140dd050b2c"><gtr:id>0189805500255a2b81f79140dd050b2c</gtr:id><gtr:otherNames>Whyte CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>iAu7rhdhyMD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>767C0073-F966-4C82-8669-300D0D1A6C9C</gtr:id><gtr:title>Monocyte and macrophage biology: an overview.</gtr:title><gtr:parentPublicationTitle>Seminars in nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3180253b5768638d6ae04bd281a86036"><gtr:id>3180253b5768638d6ae04bd281a86036</gtr:id><gtr:otherNames>Rees AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-9295</gtr:issn><gtr:outcomeId>Nepp9gxf36m</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>621F05E2-509E-40E0-96F5-9FA3A1DCBA9E</gtr:id><gtr:title>Macrophages heterogeneity in atherosclerosis - implications for therapy.</gtr:title><gtr:parentPublicationTitle>Journal of cellular and molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6efe830161e53cf9dad87fc89a05ef49"><gtr:id>6efe830161e53cf9dad87fc89a05ef49</gtr:id><gtr:otherNames>Wilson HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1582-1838</gtr:issn><gtr:outcomeId>rwrB8XFH31t</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27D839B0-A6E8-4F07-85D1-50137CD7D1B1</gtr:id><gtr:title>A critical role for suppressor of cytokine signalling 3 in promoting M1 macrophage activation and function in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85996eacd84e940a323c03f52f378181"><gtr:id>85996eacd84e940a323c03f52f378181</gtr:id><gtr:otherNames>Arnold CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>544e29eb2bd4c1.14649126</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A13A066D-0099-4BBD-8881-22DF55B4737D</gtr:id><gtr:title>Macrophage subtypes in symptomatic carotid artery and femoral artery plaques.</gtr:title><gtr:parentPublicationTitle>European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f279a825f240d43f6782bc3ccda6bf07"><gtr:id>f279a825f240d43f6782bc3ccda6bf07</gtr:id><gtr:otherNames>Shaikh S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1078-5884</gtr:issn><gtr:outcomeId>pm_15298_28_22975154</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80E70A2B-DA0E-4B2A-9DAF-F4D1E85DEE9D</gtr:id><gtr:title>Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7c92a675b6502a97a707b04cca69bc1"><gtr:id>d7c92a675b6502a97a707b04cca69bc1</gtr:id><gtr:otherNames>Liu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>C84883926FA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>256797D3-58E4-41EA-8AFF-6E00CC56F2F5</gtr:id><gtr:title>SOCS Proteins in Macrophage Polarization and Function.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6efe830161e53cf9dad87fc89a05ef49"><gtr:id>6efe830161e53cf9dad87fc89a05ef49</gtr:id><gtr:otherNames>Wilson HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>544e29eb6661f9.12373222</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500711</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>